INMB
Price
$2.53
Change
+$0.17 (+7.20%)
Updated
Jul 3 closing price
Capitalization
68.92M
23 days until earnings call
UBX
Price
$0.29
Change
-$0.01 (-3.33%)
Updated
Jul 3 closing price
Capitalization
5.04M
Interact to see
Advertisement

INMB vs UBX

Header iconINMB vs UBX Comparison
Open Charts INMB vs UBXBanner chart's image
INmune Bio
Price$2.53
Change+$0.17 (+7.20%)
Volume$4.7M
Capitalization68.92M
Unity Biotechnology
Price$0.29
Change-$0.01 (-3.33%)
Volume$1.17M
Capitalization5.04M
INMB vs UBX Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. UBX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and UBX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (INMB: $2.53 vs. UBX: $0.29)
Brand notoriety: INMB and UBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 156% vs. UBX: 149%
Market capitalization -- INMB: $68.92M vs. UBX: $5.04M
INMB [@Biotechnology] is valued at $68.92M. UBX’s [@Biotechnology] market capitalization is $5.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileUBX’s FA Score has 0 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • UBX’s FA Score: 0 green, 5 red.
According to our system of comparison, UBX is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 5 TA indicator(s) are bullish while UBX’s TA Score has 4 bullish TA indicator(s).

  • INMB’s TA Score: 5 bullish, 5 bearish.
  • UBX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both INMB and UBX are a good buy in the short-term.

Price Growth

INMB (@Biotechnology) experienced а -59.71% price change this week, while UBX (@Biotechnology) price change was -62.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($68.9M) has a higher market cap than UBX($5.04M). INMB YTD gains are higher at: -45.824 vs. UBX (-70.002). UBX has higher annual earnings (EBITDA): -24.46M vs. INMB (-41.52M). INMB has more cash in the bank: 19.3M vs. UBX (16.9M). INMB has less debt than UBX: INMB (347K) vs UBX (18.7M). INMB has higher revenues than UBX: INMB (50K) vs UBX (0).
INMBUBXINMB / UBX
Capitalization68.9M5.04M1,367%
EBITDA-41.52M-24.46M170%
Gain YTD-45.824-70.00265%
P/E RatioN/AN/A-
Revenue50K0-
Total Cash19.3M16.9M114%
Total Debt347K18.7M2%
FUNDAMENTALS RATINGS
INMB vs UBX: Fundamental Ratings
INMB
UBX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9798
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UBX's Valuation (51) in the Biotechnology industry is in the same range as INMB (82). This means that UBX’s stock grew similarly to INMB’s over the last 12 months.

UBX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INMB (100). This means that UBX’s stock grew similarly to INMB’s over the last 12 months.

INMB's SMR Rating (99) in the Biotechnology industry is in the same range as UBX (100). This means that INMB’s stock grew similarly to UBX’s over the last 12 months.

INMB's Price Growth Rating (97) in the Biotechnology industry is in the same range as UBX (98). This means that INMB’s stock grew similarly to UBX’s over the last 12 months.

INMB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as UBX (100). This means that INMB’s stock grew similarly to UBX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBUBX
RSI
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
87%
Momentum
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 5 days ago
85%
MACD
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 18 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 5 days ago
72%
Aroon
ODDS (%)
Bullish Trend 5 days ago
78%
Bearish Trend 5 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APLS18.260.44
+2.47%
Apellis Pharmaceuticals
RGA197.791.70
+0.87%
Reinsurance Group of America
LSEA11.31N/A
N/A
Landsea Homes Corp
CMTL2.60-0.01
-0.38%
Comtech Telecommunications Corp
AMBO2.46-0.05
-1.90%
Ambow Education Holding Ltd

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UBX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
+7.20%
UBX - INMB
55%
Loosely correlated
-1.71%
ABCL - INMB
46%
Loosely correlated
+1.33%
GBIO - INMB
36%
Loosely correlated
+1.51%
PROK - INMB
36%
Loosely correlated
+10.11%
OVID - INMB
35%
Loosely correlated
+2.39%
More

UBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, UBX has been loosely correlated with INMB. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if UBX jumps, then INMB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UBX
1D Price
Change %
UBX100%
-1.71%
INMB - UBX
54%
Loosely correlated
+7.20%
HOFBF - UBX
34%
Loosely correlated
N/A
ABCL - UBX
33%
Loosely correlated
+1.33%
LRMR - UBX
30%
Poorly correlated
+2.89%
CVAC - UBX
29%
Poorly correlated
+0.93%
More